Description: This session discussion is about high cost claimants in medical benefit plans and how to control costs and anti-selection. From Record of the Society of Actuaries Vol. 15, No. 3B.

Description: The coming wave of biosimilars could dramatically affect prescription drug costs and benefit strategies over the next several years. The launch of many Humira biosimilars in 2023 is the Big Event that will largely determine the impact of the biosimilar wave. Payers have many decisions to make about coverage and formulary tiers. What factors will drive payer decision-making?